Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
Reed Friend, Manisha Bhutani, Peter M Voorhees, Saad Z Usmani Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA Abstract: Elotuzumab is one of the first monoclonal antibodies to be approved for t...
Saved in:
Main Authors: | Friend R (Author), Bhutani M (Author), Voorhees PM (Author), Usmani SZ (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elotuzumab as a novel anti-myeloma immunotherapy
by: Sabarinath Venniyil Radhakrishnan, et al.
Published: (2017) -
Rescue SLAMF7 activity in exhausted natural killer cells: Novel challenges in the immunotherapy of multiple myeloma
by: Alessandra Zingoni, et al.
Published: (2022) -
Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma
by: Omar Castaneda-Puglianini, et al.
Published: (2021) -
Anti CD38 monoclonal antibodies for multiple myeloma treatment
by: Alessandro Gozzetti, et al.
Published: (2022) -
Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
by: Upasana Ray, et al.
Published: (2023)